Latest Market News

Tinybeans Group announces a leadership reshuffle with Tracy Cho as Interim CEO and Rebecca White joining the Board, sharpening its focus on expanding in the lucrative U.S. family market.

Argent BioPharma has completed its largest commercial shipment of CannEpil® to Ireland, marking a key milestone in its European expansion with a delivery valued at approximately AUD 783,000. The product is fully reimbursed under Ireland’s National Health Insurance scheme, enhancing patient access for refractory epilepsy treatment.

Bindi Metals has secured regulatory approval to commence its maiden drilling program at the Ravni Gold Project in Serbia, while historic drill core resampling is underway with assay results expected soon.

Navigator Global Investments reported a 17% rise in adjusted EBITDA to USD48.2 million for H1 FY26, driven by strong performance fees and asset growth, though full-year earnings face headwinds.

Medallion Metals Limited has extended the deadline for its acquisition of the Forrestania Nickel Operation from IGO Limited, with completion expected by 27 February 2026. The transaction remains on track despite a few outstanding conditions.

Pantoro Gold has announced a significant on-market share buy-back of up to 10% of its shares, leveraging strong cashflow from its Norseman Gold Project to enhance shareholder value while funding growth.

VEEM Limited reports half-year revenue close to guidance with improved cash flow, offset by a significant $24.8 million non-cash impairment tied to its gyro product upgrade. The transition to the new Mark III gyro design has temporarily stalled sales as customers await delivery.

A recent expert panel convened by Novitas has strongly endorsed Pacific Edge’s urine-based Cxbladder tests for hematuria evaluation, recommending Medicare coverage based on robust clinical evidence and patient care benefits.

Tivan Limited has submitted a confidential draft Feasibility Study for its Speewah Fluorite Project to key partners, marking a significant step towards project finalisation and potential production.

Clarity Pharmaceuticals reports another metastatic prostate cancer patient achieving undetectable disease markers in its Phase II SECuRE trial, reinforcing promising efficacy and safety of its Cu-SAR-bisPSMA radiopharmaceutical.

Symal Group Limited reported a robust half-year performance with revenues climbing 24.6% to $504.2 million and announced key acquisitions to bolster its infrastructure footprint. The company also secured $300 million in new debt facilities to support its expansion plans.

Adairs Limited reported a solid 5.9% increase in sales for the half year ended December 2025, driven by strong brand performances, especially Mocka. However, underlying EBIT declined 9.1% due to margin pressures and rising costs, while the company declared a fully franked interim dividend.